Which has better earnings and valuation, INDV or IMTX?

Indivior has higher revenue and earnings than Immatics. Immatics is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Indivior $1.24B 3.85 $210M $1.95 20.06 Immatics $54.60M 22.66 -$222.26M -$1.99 N/A

Is INDV or IMTX more profitable?

Indivior has a net margin of 19.44% compared to Immatics' net margin of -572.35%. Immatics' return on equity of -47.36% beat Indivior's return on equity. Company Net Margins Return on Equity Return on Assets Indivior 19.44% -219.26% 29.40% Immatics -572.35% -47.36% -39.35%

Does the media prefer INDV or IMTX?

In the previous week, Indivior and Indivior both had 2 articles in the media. Immatics' average media sentiment score of 0.93 beat Indivior's score of 0.42 indicating that Immatics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Indivior 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Immatics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, IMTX or CRSP?

Immatics has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immatics $54.60M 22.66 -$222.26M -$1.99 N/A CRISPR Therapeutics $3.51M 1,291.22 -$581.60M -$6.22 N/A

Does the media favor IMTX or CRSP?

In the previous week, CRISPR Therapeutics had 8 more articles in the media than Immatics. MarketBeat recorded 10 mentions for CRISPR Therapeutics and 2 mentions for Immatics. Immatics' average media sentiment score of 0.93 beat CRISPR Therapeutics' score of 0.71 indicating that Immatics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immatics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CRISPR Therapeutics 5 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor IMTX or KNSA?

In the previous week, Immatics and Immatics both had 2 articles in the media. Immatics' average media sentiment score of 0.93 beat Kiniksa Pharmaceuticals International's score of 0.82 indicating that Immatics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immatics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kiniksa Pharmaceuticals International 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, GRFS or IMTX?

Grifols has higher revenue and earnings than Immatics. Immatics is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Grifols $8.51B 0.61 $454.82M $0.19 40.05 Immatics $54.60M 22.66 -$222.26M -$1.99 N/A

Is GRFS or IMTX more profitable?

Grifols has a net margin of 5.54% compared to Immatics' net margin of -572.35%. Grifols' return on equity of 6.21% beat Immatics' return on equity. Company Net Margins Return on Equity Return on Assets Grifols 5.54% 6.21% 2.39% Immatics -572.35% -47.36% -39.35%

Does the media prefer GRFS or IMTX?

In the previous week, Immatics had 1 more articles in the media than Grifols. MarketBeat recorded 2 mentions for Immatics and 1 mentions for Grifols. Immatics' average media sentiment score of 0.93 beat Grifols' score of 0.00 indicating that Immatics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Grifols 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Immatics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is LEGN or IMTX more profitable?

Legend Biotech has a net margin of -21.98% compared to Immatics' net margin of -572.35%. Legend Biotech's return on equity of -24.92% beat Immatics' return on equity. Company Net Margins Return on Equity Return on Assets Legend Biotech -21.98% -24.92% -14.87% Immatics -572.35% -47.36% -39.35%

Does the media prefer LEGN or IMTX?

In the previous week, Legend Biotech had 7 more articles in the media than Immatics. MarketBeat recorded 9 mentions for Legend Biotech and 2 mentions for Immatics. Immatics' average media sentiment score of 0.93 beat Legend Biotech's score of 0.61 indicating that Immatics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Legend Biotech 1 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immatics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Immatics (IMTX) Competitors

$9.23 -0.36 (-3.75%)

Closing price 07/20/2026 04:00 PM Eastern

Extended Trading

$9.24 +0.00 (+0.05%)

As of 07/20/2026 07:56 PM Eastern

Compare

IMTX vs. INDV, CRSP, KNSA, GRFS, and LEGN

Should you buy Immatics stock or one of its competitors? MarketBeat compares Immatics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Immatics include Indivior (INDV), CRISPR Therapeutics (CRSP), Kiniksa Pharmaceuticals International (KNSA), Grifols (GRFS), and Legend Biotech (LEGN). These companies are all part of the "pharmaceutical products" industry.

How does Immatics compare to Indivior?

Indivior (NASDAQ:INDV) and Immatics (NASDAQ:IMTX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, media sentiment, risk, institutional ownership, earnings and analyst recommendations.

60.3% of Indivior shares are owned by institutional investors. Comparatively, 64.4% of Immatics shares are owned by institutional investors. 0.7% of Indivior shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Indivior and Indivior both had 2 articles in the media. Immatics' average media sentiment score of 0.93 beat Indivior's score of 0.42 indicating that Immatics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Indivior	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immatics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Indivior has higher revenue and earnings than Immatics. Immatics is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indivior	$1.24B	3.85	$210M	$1.95	20.06
Immatics	$54.60M	22.66	-$222.26M	-$1.99	N/A

Indivior has a beta of 0.86, meaning that its share price is 14% less volatile than the broader market. Comparatively, Immatics has a beta of 1.32, meaning that its share price is 32% more volatile than the broader market.

Indivior currently has a consensus target price of $40.29, suggesting a potential upside of 2.98%. Immatics has a consensus target price of $20.80, suggesting a potential upside of 125.35%. Given Immatics' higher possible upside, analysts clearly believe Immatics is more favorable than Indivior.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indivior	0 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.75
Immatics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Indivior has a net margin of 19.44% compared to Immatics' net margin of -572.35%. Immatics' return on equity of -47.36% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indivior	19.44%	-219.26%	29.40%
Immatics	-572.35%	-47.36%	-39.35%

Summary

Indivior beats Immatics on 8 of the 14 factors compared between the two stocks.

How does Immatics compare to CRISPR Therapeutics?

Immatics (NASDAQ:IMTX) and CRISPR Therapeutics (NASDAQ:CRSP) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings.

Immatics has a beta of 1.32, meaning that its share price is 32% more volatile than the broader market. Comparatively, CRISPR Therapeutics has a beta of 1.71, meaning that its share price is 71% more volatile than the broader market.

64.4% of Immatics shares are owned by institutional investors. Comparatively, 69.2% of CRISPR Therapeutics shares are owned by institutional investors. 5.2% of CRISPR Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, CRISPR Therapeutics had 8 more articles in the media than Immatics. MarketBeat recorded 10 mentions for CRISPR Therapeutics and 2 mentions for Immatics. Immatics' average media sentiment score of 0.93 beat CRISPR Therapeutics' score of 0.71 indicating that Immatics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immatics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CRISPR Therapeutics	5 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Immatics has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immatics	$54.60M	22.66	-$222.26M	-$1.99	N/A
CRISPR Therapeutics	$3.51M	1,291.22	-$581.60M	-$6.22	N/A

Immatics presently has a consensus target price of $20.80, indicating a potential upside of 125.35%. CRISPR Therapeutics has a consensus target price of $67.78, indicating a potential upside of 44.24%. Given Immatics' stronger consensus rating and higher probable upside, research analysts plainly believe Immatics is more favorable than CRISPR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immatics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
CRISPR Therapeutics	1 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.58

Immatics has a net margin of -572.35% compared to CRISPR Therapeutics' net margin of -13,856.54%. CRISPR Therapeutics' return on equity of -25.66% beat Immatics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immatics	-572.35%	-47.36%	-39.35%
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%

Summary

CRISPR Therapeutics beats Immatics on 9 of the 17 factors compared between the two stocks.

How does Immatics compare to Kiniksa Pharmaceuticals International?

Immatics (NASDAQ:IMTX) and Kiniksa Pharmaceuticals International (NASDAQ:KNSA) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership.

Immatics has a beta of 1.32, meaning that its share price is 32% more volatile than the broader market. Comparatively, Kiniksa Pharmaceuticals International has a beta of 0.07, meaning that its share price is 93% less volatile than the broader market.

Kiniksa Pharmaceuticals International has higher revenue and earnings than Immatics. Immatics is trading at a lower price-to-earnings ratio than Kiniksa Pharmaceuticals International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immatics	$54.60M	22.66	-$222.26M	-$1.99	N/A
Kiniksa Pharmaceuticals International	$677.56M	7.11	$59.01M	$0.90	69.53

Immatics currently has a consensus price target of $20.80, indicating a potential upside of 125.35%. Kiniksa Pharmaceuticals International has a consensus price target of $65.14, indicating a potential upside of 4.10%. Given Immatics' higher possible upside, equities research analysts clearly believe Immatics is more favorable than Kiniksa Pharmaceuticals International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immatics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Kiniksa Pharmaceuticals International	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	3.00

64.4% of Immatics shares are owned by institutional investors. Comparatively, 54.0% of Kiniksa Pharmaceuticals International shares are owned by institutional investors. 52.0% of Kiniksa Pharmaceuticals International shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Kiniksa Pharmaceuticals International has a net margin of 9.69% compared to Immatics' net margin of -572.35%. Kiniksa Pharmaceuticals International's return on equity of 13.26% beat Immatics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immatics	-572.35%	-47.36%	-39.35%
Kiniksa Pharmaceuticals International	9.69%	13.26%	9.86%

In the previous week, Immatics and Immatics both had 2 articles in the media. Immatics' average media sentiment score of 0.93 beat Kiniksa Pharmaceuticals International's score of 0.82 indicating that Immatics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immatics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Kiniksa Pharmaceuticals International	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Kiniksa Pharmaceuticals International beats Immatics on 11 of the 16 factors compared between the two stocks.

How does Immatics compare to Grifols?

Grifols (NASDAQ:GRFS) and Immatics (NASDAQ:IMTX) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings, profitability and risk.

In the previous week, Immatics had 1 more articles in the media than Grifols. MarketBeat recorded 2 mentions for Immatics and 1 mentions for Grifols. Immatics' average media sentiment score of 0.93 beat Grifols' score of 0.00 indicating that Immatics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Grifols	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immatics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Grifols has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market. Comparatively, Immatics has a beta of 1.32, indicating that its stock price is 32% more volatile than the broader market.

64.4% of Immatics shares are held by institutional investors. 0.2% of Grifols shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Grifols currently has a consensus target price of $10.00, indicating a potential upside of 31.41%. Immatics has a consensus target price of $20.80, indicating a potential upside of 125.35%. Given Immatics' stronger consensus rating and higher probable upside, analysts clearly believe Immatics is more favorable than Grifols.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Grifols	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
Immatics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Grifols has a net margin of 5.54% compared to Immatics' net margin of -572.35%. Grifols' return on equity of 6.21% beat Immatics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Grifols	5.54%	6.21%	2.39%
Immatics	-572.35%	-47.36%	-39.35%

Grifols has higher revenue and earnings than Immatics. Immatics is trading at a lower price-to-earnings ratio than Grifols, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Grifols	$8.51B	0.61	$454.82M	$0.19	40.05
Immatics	$54.60M	22.66	-$222.26M	-$1.99	N/A

Summary

Grifols and Immatics tied by winning 8 of the 16 factors compared between the two stocks.

How does Immatics compare to Legend Biotech?

Legend Biotech (NASDAQ:LEGN) and Immatics (NASDAQ:IMTX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, media sentiment, dividends and profitability.

70.9% of Legend Biotech shares are held by institutional investors. Comparatively, 64.4% of Immatics shares are held by institutional investors. 0.0% of Legend Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Legend Biotech has a beta of 0.34, suggesting that its stock price is 66% less volatile than the broader market. Comparatively, Immatics has a beta of 1.32, suggesting that its stock price is 32% more volatile than the broader market.

Legend Biotech currently has a consensus target price of $57.00, indicating a potential upside of 145.58%. Immatics has a consensus target price of $20.80, indicating a potential upside of 125.35%. Given Legend Biotech's higher possible upside, research analysts plainly believe Legend Biotech is more favorable than Immatics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Legend Biotech	1 Sell rating(s)	4 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.57
Immatics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

Legend Biotech has a net margin of -21.98% compared to Immatics' net margin of -572.35%. Legend Biotech's return on equity of -24.92% beat Immatics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Legend Biotech	-21.98%	-24.92%	-14.87%
Immatics	-572.35%	-47.36%	-39.35%

Immatics has lower revenue, but higher earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Legend Biotech	$1.03B	4.19	-$296.80M	-$0.68	N/A
Immatics	$54.60M	22.66	-$222.26M	-$1.99	N/A

In the previous week, Legend Biotech had 7 more articles in the media than Immatics. MarketBeat recorded 9 mentions for Legend Biotech and 2 mentions for Immatics. Immatics' average media sentiment score of 0.93 beat Legend Biotech's score of 0.61 indicating that Immatics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Legend Biotech	1 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immatics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Legend Biotech beats Immatics on 10 of the 16 factors compared between the two stocks.

Get Immatics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMTX vs. The Competition

Export

Metric	Immatics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.29B	$3.69B	$6.89B	$12.28B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-4.64	20.49	27.06	23.94
Price / Sales	22.66	300.33	514.89	90.87
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	2.26	7.92	10.66	6.14
Net Income	-$222.26M	$23.81M	$3.60B	$331.74M
7 Day Performance	-1.28%	-1.09%	-1.23%	-1.81%
1 Month Performance	-5.62%	2.56%	1.11%	-1.44%
1 Year Performance	57.78%	42.16%	23.65%	16.33%

Immatics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMTX Immatics	2.4091 of 5 stars	$9.23 -3.8%	$20.80 +125.4%	+53.8%	$1.29B	$54.60M	N/A	260
INDV Indivior	2.2566 of 5 stars	$40.37 +0.4%	$40.29 -0.2%	+144.3%	$4.91B	$1.24B	20.67	1,051
CRSP CRISPR Therapeutics	3.4125 of 5 stars	$50.71 +0.1%	$67.78 +33.7%	-27.9%	$4.87B	$3.51M	N/A	460
KNSA Kiniksa Pharmaceuticals International	2.995 of 5 stars	$62.49 +2.5%	$65.14 +4.3%	+115.6%	$4.80B	$677.56M	69.26	220	Upcoming Earnings
GRFS Grifols	4.0144 of 5 stars	$7.02 -2.6%	$10.00 +42.6%	-23.4%	$4.78B	$7.44B	36.97	25,247	Upcoming Earnings Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMTX) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immatics (IMTX) Competitors

IMTX vs. INDV, CRSP, KNSA, GRFS, and LEGN

How does Immatics compare to Indivior?

Summary

How does Immatics compare to CRISPR Therapeutics?

Summary

How does Immatics compare to Kiniksa Pharmaceuticals International?

Summary

How does Immatics compare to Grifols?

Summary

How does Immatics compare to Legend Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMTX vs. The Competition

Immatics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immatics (IMTX) Competitors

IMTX vs. INDV, CRSP, KNSA, GRFS, and LEGN

How does Immatics compare to Indivior?

Do institutionals and insiders have more ownership in INDV or IMTX?

Does the media prefer INDV or IMTX?

Which has better earnings and valuation, INDV or IMTX?

Which has more volatility & risk, INDV or IMTX?

Do analysts rate INDV or IMTX?

Is INDV or IMTX more profitable?

Summary

How does Immatics compare to CRISPR Therapeutics?

Which has more risk and volatility, IMTX or CRSP?

Do institutionals & insiders believe in IMTX or CRSP?

Does the media favor IMTX or CRSP?

Which has better earnings & valuation, IMTX or CRSP?

Do analysts recommend IMTX or CRSP?

Is IMTX or CRSP more profitable?

Summary

How does Immatics compare to Kiniksa Pharmaceuticals International?

Which has more volatility and risk, IMTX or KNSA?

Which has preferable earnings & valuation, IMTX or KNSA?

Do analysts prefer IMTX or KNSA?

Do institutionals and insiders have more ownership in IMTX or KNSA?

Is IMTX or KNSA more profitable?

Does the media favor IMTX or KNSA?

Summary

How does Immatics compare to Grifols?

Does the media prefer GRFS or IMTX?

Which has more risk and volatility, GRFS or IMTX?

Do institutionals & insiders have more ownership in GRFS or IMTX?

Do analysts rate GRFS or IMTX?

Is GRFS or IMTX more profitable?

Which has preferable valuation and earnings, GRFS or IMTX?

Summary

How does Immatics compare to Legend Biotech?

Do insiders and institutionals believe in LEGN or IMTX?

Which has more volatility and risk, LEGN or IMTX?

Do analysts prefer LEGN or IMTX?

Is LEGN or IMTX more profitable?

Which has better valuation and earnings, LEGN or IMTX?

Does the media prefer LEGN or IMTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMTX vs. The Competition

Immatics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools